+

CU23674A1 - Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica - Google Patents

Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Info

Publication number
CU23674A1
CU23674A1 CU20070180A CU20070180A CU23674A1 CU 23674 A1 CU23674 A1 CU 23674A1 CU 20070180 A CU20070180 A CU 20070180A CU 20070180 A CU20070180 A CU 20070180A CU 23674 A1 CU23674 A1 CU 23674A1
Authority
CU
Cuba
Prior art keywords
penetrating peptides
biomolecle
fusioned
cells
therapeutic action
Prior art date
Application number
CU20070180A
Other languages
English (en)
Inventor
Rodriguez Milaid Granadillo
Madrazo Isis Del Carmen Torrens
Castro Boris Ernesto Acevedo
Acosta Osvaldo Reyes
Vallespi Maribel Guerra
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20070180A priority Critical patent/CU23674A1/es
Priority to ARP080103311A priority patent/AR068329A1/es
Priority to EP08784156.5A priority patent/EP2186526B1/en
Priority to CA2694735A priority patent/CA2694735C/en
Priority to CN2008801095459A priority patent/CN101808658B/zh
Priority to PCT/CU2008/000006 priority patent/WO2009021468A1/es
Priority to US12/671,335 priority patent/US8673313B2/en
Priority to KR1020107004635A priority patent/KR101515445B1/ko
Priority to ES08784156.5T priority patent/ES2610408T3/es
Priority to BRPI0814452-4A2A priority patent/BRPI0814452A2/pt
Priority to ZA2010/01337A priority patent/ZA201001337B/en
Publication of CU23674A1 publication Critical patent/CU23674A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se encuadra dentro del campo de la inmunología, la biología celular y el cáncer. Se refiere a péptidos penetradores a células (PPC) y en particular a la región 32-51 de la proteína Limulus antilipopolisacárido (LALF) y sus análogos, los cuales asociados a una biomolécula forman una proteína de fusión con propiedades terapéuticas. Estas proteínas contienen la fusión covalente o conjugada e estos PPC o antígenos de origen viral, bacteriano o tumoral, como el virus de papiloma humano (VPH) u otras biomoléculas, para inducir una potente respuesta inmune celular contra tumores. Las proteínas referidas son aplicables en la industria farmacéutica como vacunas para uso terapéutico en humano.
CU20070180A 2007-07-31 2007-07-31 Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica CU23674A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU20070180A CU23674A1 (es) 2007-07-31 2007-07-31 Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
ARP080103311A AR068329A1 (es) 2007-07-31 2008-07-30 Peptidos penetradores a celulas y su uso fusionados a biomoleculas con accion terapeutica
EP08784156.5A EP2186526B1 (en) 2007-07-31 2008-07-31 Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action
CA2694735A CA2694735C (en) 2007-07-31 2008-07-31 Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action
CN2008801095459A CN101808658B (zh) 2007-07-31 2008-07-31 细胞穿透肽及其与具有治疗作用的生物分子相融合的用途
PCT/CU2008/000006 WO2009021468A1 (es) 2007-07-31 2008-07-31 Péptidos penetradores a células y su uso fusionados a biomoléculas con acción terapéutica
US12/671,335 US8673313B2 (en) 2007-07-31 2008-07-31 Cell penetrating peptides and its use fused to biomolecules with therapeutic action
KR1020107004635A KR101515445B1 (ko) 2007-07-31 2008-07-31 세포 투과 펩타이드 및 치료 작용을 갖는 생체 분자에 결합된 이의 용도
ES08784156.5T ES2610408T3 (es) 2007-07-31 2008-07-31 Péptidos de penetración a células y su uso fusionados a biomoléculas con acción terapéutica
BRPI0814452-4A2A BRPI0814452A2 (pt) 2007-07-31 2008-07-31 Composição que contém um peptídeo penetrador em células, uso de uma composição farmacêutica e método de tratamento de um tumor
ZA2010/01337A ZA201001337B (en) 2007-07-31 2010-02-24 Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070180A CU23674A1 (es) 2007-07-31 2007-07-31 Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Publications (1)

Publication Number Publication Date
CU23674A1 true CU23674A1 (es) 2011-05-27

Family

ID=39864865

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070180A CU23674A1 (es) 2007-07-31 2007-07-31 Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Country Status (11)

Country Link
US (1) US8673313B2 (es)
EP (1) EP2186526B1 (es)
KR (1) KR101515445B1 (es)
CN (1) CN101808658B (es)
AR (1) AR068329A1 (es)
BR (1) BRPI0814452A2 (es)
CA (1) CA2694735C (es)
CU (1) CU23674A1 (es)
ES (1) ES2610408T3 (es)
WO (1) WO2009021468A1 (es)
ZA (1) ZA201001337B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23896B1 (es) 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
CU23897B1 (es) * 2010-05-31 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Péptido para la terapia del cáncer
CN102212124B (zh) * 2011-05-17 2012-07-18 厦门大学 拟穴青蟹抗脂多糖因子及其制备方法与应用
EP2861737B1 (en) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
WO2014199358A1 (en) 2013-06-14 2014-12-18 Cellectis Methods for non-transgenic genome editing in plants
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR101799805B1 (ko) 2016-04-07 2017-11-21 (주)네오리젠바이오텍 세포 투과 펩티드
KR102484312B1 (ko) * 2020-05-14 2023-01-02 한국화학연구원 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907721A1 (de) 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
JPH06503559A (ja) 1990-12-12 1994-04-21 ザ・ユニバーシティ・オブ・クイーンズランド サブユニット・パピローマウイルス・ワクチンおよびそれに使用するペプチド
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
IL134341A0 (en) 1997-08-05 2001-04-30 Stressgen Biotechnologies Corp Compositions for inducing an immune response containing an hpv protein antigen
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
CU23582A1 (es) * 2006-02-24 2010-10-30 Ct Ingenieria Genetica Biotech Péptidos con capacidad anti-tumoral e inmunomoduladora

Also Published As

Publication number Publication date
AR068329A1 (es) 2009-11-11
ZA201001337B (en) 2010-11-24
WO2009021468A1 (es) 2009-02-19
EP2186526A1 (en) 2010-05-19
KR101515445B1 (ko) 2015-05-07
CA2694735A1 (en) 2009-02-19
CN101808658B (zh) 2013-10-23
US20120135021A1 (en) 2012-05-31
ES2610408T3 (es) 2017-04-27
KR20100045498A (ko) 2010-05-03
CN101808658A (zh) 2010-08-18
CA2694735C (en) 2014-09-09
US8673313B2 (en) 2014-03-18
BRPI0814452A2 (pt) 2015-01-06
EP2186526B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
CU23674A1 (es) Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
CY1123854T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου του προστατη και αλλων καρκινων
CY1124224T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων
CY1123902T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι tου καρκινου του οισοφαγου και αλλων καρκινων
EA201891701A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии немелкоклеточного рака легких и других видов рака
CY1123505T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του επιθηλιακου καρκινου των ωοθηκων και αλλων καρκινων
MX2018004140A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer.
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
MX2018005372A (es) Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra la leucemia linfocitica cronica (cll) y otros tipos de cancer.
MX2018005374A (es) Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer.
MX2018005273A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer.
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
EA201891670A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
MX385679B (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
EA201891994A1 (ru) Лечение рака матки
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
EA201992664A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
MX2021013003A (es) Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres.
MX2018013081A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
MX2018010875A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
EA201892159A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака
CL2024000530A1 (es) Péptidos y combinaciones, su uso en la inmunoterapia contra cáncer de pulmón y otros cánceres
EA201991444A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载